Clinical Study
A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen
Table 6
Causes of death in 13 patients.
| ||||||||||||||||||||||||||
Within 30 days after last lenograstim administration. |